Sun, Feb 1, 2015, 12:33 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Cleveland BioLabs, Inc. Message Board

fjmulvz 3 posts  |  Last Activity: Dec 3, 2014 1:09 PM Member since: Mar 20, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    What comes first?

    by fpmiike Dec 2, 2014 11:28 AM
    fjmulvz fjmulvz Dec 3, 2014 1:09 PM Flag

    I vote for the partnership/government funding.

    Get your popcorn ready...

  • Reply to

    Specific, new funding avenue

    by justrpaul Nov 18, 2014 9:34 AM
    fjmulvz fjmulvz Dec 1, 2014 10:43 AM Flag

    Drugs that allow the immune system to recognise cancer and attack it are continuing to produce "exciting" results, say experts in the field.

    The comments come after a series of studies were published in Nature this week, highlighting further progress in the field of immunotherapy.

    One report contained details of a small (phase 1) clinical trial looking at bladder cancer carried out by Dr Thomas Powles from the Barts Cancer Institute, and colleagues.

    Dr Powles pointed out that there have been no major advances for patients with advanced bladder cancer for 30 years, with chemotherapy still the main treatment option. Outcomes for patients with this stage of bladder cancer are poor.

    However, there was a promising response among patients on the trial, which involved a drug that targets a protein, called PD-L1, which tumours use to trick the immune system.

    Of the 68 patients who were given the drug, produced by Roche, more than half showed signs of effectiveness, and – in a minority – the drugs produced a long lasting response.

    Professor Peter Johnson, Cancer Research UK's chief clinician, said: "We're seeing a lot of very exciting results from these new treatments using the immune system. This study in bladder cancer is further proof of the power of this approach, and it's really good to find a new treatment for a type of cancer that we've been struggling to make progress with for many years.

    "Cancer can only grow by finding a way to escape detection by the immune system. One way it does this is to trigger a shut-off switch on immune cells when they get close to the tumour. This new treatment blocks the cancer cell's ability to use this switch, allowing the immune system to recognise and destroy the cancer".

    Another study in the area by Dr Roy Herbst, from the Yale Cancer Centre in the US, demonstrated that such treatments can produce responses in patients with other cancers, including lung and kidney cancers, and melanoma skin cancers.

  • Reply to

    Specific, new funding avenue

    by justrpaul Nov 18, 2014 9:34 AM
    fjmulvz fjmulvz Nov 21, 2014 3:37 PM Flag

    Get a deal done.

    Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland (21-22 November)

    "We expect that the new possibilities of immunotherapy will substantially change the treatment of cancer," said Stahel, who is also Scientific Co-Chair of the meeting. "And this is not just in one disease, but across the board in many types of cancer. The ESMO Symposium on Immuno-Oncology will highlight all exciting immunotherapy topics which are now on the verge of entering clinical practice or are already practiced in some of the leading centres."

    Professor George Coukos, also Scientific Co-Chair of the meeting, director of the Department of Oncology at the University Hospital of Lausanne (CHUV) and the Ludwig Cancer Research Centre, Lausanne, Switzerland, said: "There is no doubt that immunotherapy is rapidly emerging as a self-standing therapeutic domain in oncology. This is in the same way that chemotherapy, molecular targeted therapies, radiation therapy or surgery have made a very significant contribution to the treatment of cancer patients."

    The latest developments in immunotherapy will be presented by international experts from Europe and beyond on topics including checkpoint blockade, T cell therapies and vaccine development.

CBLI
3.93-0.28(-6.65%)Jan 30 3:57 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.